Loading...

Ralph W deVere White

Title(s)Professor, Urology
SchoolUniversity of California, Davis
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wang S, Scharadin TM, Zimmermann M, Malfatti MA, Turteltaub KW, de Vere White R, Pan CX, Henderson PT. Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel. Chem Res Toxicol. 2018 12 17; 31(12):1293-1304. PMID: 30381944.
      View in: PubMed
    2. Yap SA, Brunson A, Pugashetti N, M P H RDC, Keegan THM, deVere White R, Wun T. Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence. Urol Oncol. 2018 11; 36(11):498.e1-498.e7. PMID: 30236855.
      View in: PubMed
    3. Dall'Era MA, De Vere White RW. New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose? Eur Urol. 2018 11; 74(5):549-550. PMID: 30177292.
      View in: PubMed
    4. Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, Hu Z, Wun T, Lara PN, DeVere White RW, Chen HW, Yu AM. Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. J Pharmacol Exp Ther. 2018 06; 365(3):494-506. PMID: 29602831.
      View in: PubMed
    5. Long Q, Lin TY, Huang Y, Li X, Ma AH, Zhang H, Carney R, Airhart S, Lam KS, deVere White RW, Pan CX, Li Y. Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine. 2018 04; 14(3):789-799. PMID: 29317342.
      View in: PubMed
    6. Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, Shi W, Ma AH, De Vere White RW, Airhart S, Liu ET, Banchereau J, Brehm MA, Greiner DL, Shultz LD, Palucka K, Keck JG. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018 03; 32(3):1537-1549. PMID: 29146734.
      View in: PubMed
    7. Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX. COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther. 2018 02; 17(2):474-483. PMID: 29284644.
      View in: PubMed
    8. Gheibi P, Zeng S, Son KJ, Vu T, Ma AH, Dall'Era MA, Yap SA, de Vere White RW, Pan CX, Revzin A. Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. Sci Rep. 2017 09 25; 7(1):12277. PMID: 28947782.
      View in: PubMed
    9. Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, Guo JM, Xu CL, deVere White RW, Pan CX. The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res. 2017 Nov 01; 23(21):6580-6591. PMID: 28808038.
      View in: PubMed
    10. D'Abronzo LS, Bose S, Crapuchettes ME, Beggs RE, Vinall RL, Tepper CG, Siddiqui S, Mudryj M, Melgoza FU, Durbin-Johnson BP, deVere White RW, Ghosh PM. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer. Oncogene. 2017 11 16; 36(46):6359-6373. PMID: 28745319.
      View in: PubMed
    11. Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson PT. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. Int J Cancer. 2017 08 01; 141(3):604-613. PMID: 28437852.
      View in: PubMed
    12. de Vere White R. Re: Management of Nonmuscle Invasive Bladder Cancer: A Comprehensive Analysis of Guidelines from the Unites States, Europe, and Asia. Eur Urol. 2017 04; 71(4):688. PMID: 28073601.
      View in: PubMed
    13. Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Mol Cancer Ther. 2017 02; 16(2):376-387. PMID: 27903751.
      View in: PubMed
    14. Scharadin TM, Zhang H, Zimmermann M, Wang S, Malfatti MA, Cimino GD, Turteltaub K, de Vere White R, Pan CX, Henderson PT. Diagnostic Microdosing Approach to Study Gemcitabine Resistance. Chem Res Toxicol. 2016 11 21; 29(11):1843-1848. PMID: 27657672.
      View in: PubMed
    15. Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016 Oct 21; 27(42):425103. PMID: 27640312.
      View in: PubMed
    16. Lin TY, Li Y, Liu Q, Chen JL, Zhang H, Lac D, Zhang H, Ferrara KW, Wachsmann-Hogiu S, Li T, Airhart S, deVere White R, Lam KS, Pan CX. Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer. Biomaterials. 2016 10; 104:339-51. PMID: 27479049.
      View in: PubMed
    17. Lara J, Brunson A, Keegan TH, Malogolowkin M, Pan CX, Yap S, deVere White R. Determinants of Survival for Adolescents and Young Adults with Urothelial Bladder Cancer: Results from the California Cancer Registry. J Urol. 2016 11; 196(5):1378-1382. PMID: 27208515.
      View in: PubMed
    18. Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 06 15; 122(12):1897-904. PMID: 27019001.
      View in: PubMed
    19. Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson PT. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. PLoS One. 2016; 11(1):e0146256. PMID: 26799320.
      View in: PubMed
    20. Shi XB, Ma AH, Xue L, Li M, Nguyen HG, Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ, deVere White RW. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Res. 2015 Dec 15; 75(24):5309-17. PMID: 26573802.
      View in: PubMed
    21. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One. 2015; 10(8):e0134346. PMID: 26270481.
      View in: PubMed
    22. Wang WP, Ho PY, Chen QX, Addepalli B, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, Li T, Wun T, White RD, Lam KS, Yu AM. Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization. J Pharmacol Exp Ther. 2015 Aug; 354(2):131-41. PMID: 26022002.
      View in: PubMed
    23. Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. PMID: 25838158.
      View in: PubMed
    24. Mooso BA, Vinall RL, Mudryj M, Yap SA, deVere White RW, Ghosh PM. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol. 2015 Jan; 193(1):19-29. PMID: 25158272.
      View in: PubMed
    25. Thieu W, Tilki D, de Vere White R, Evans CP. The role of microRNA in castration-resistant prostate cancer. Urol Oncol. 2014 Jul; 32(5):517-523. PMID: 24935732.
      View in: PubMed
    26. de Vere White R, Lara PN. Toward a common therapeutic framework in castration-resistant prostate cancer: a model for urologic oncology and medical oncology interaction. Urol Oncol. 2014 May; 32(4):380-2. PMID: 24316022.
      View in: PubMed
    27. White RW. Legends in urology. Can J Urol. 2014 Apr; 21(2):7176-8. PMID: 24775566.
      View in: PubMed
    28. Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN, DeVere White RW, Gao AC, Evans CP. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014 Sep 04; 33(36):4521-30. PMID: 24662833.
      View in: PubMed
    29. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014 Mar 15; 120(6):818-23. PMID: 24258693.
      View in: PubMed
    30. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, deVere White RW, Kung HJ. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 2014 May 08; 33(19):2495-503. PMID: 23728339.
      View in: PubMed
    31. Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere White RW. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS One. 2013; 8(4):e61064. PMID: 23585871.
      View in: PubMed
    32. Lin TY, Li YP, Zhang H, Luo J, Goodwin N, Gao T, White Rde V, Lam KS, Pan CX. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine (Lond). 2013 Aug; 8(8):1239-51. PMID: 23199207.
      View in: PubMed
    33. Mooso BA, Vinall RL, Tepper CG, Savoy RM, Cheung JP, Singh S, Siddiqui S, Wang Y, Bedolla RG, Martinez A, Mudryj M, Kung HJ, Devere White RW, Ghosh PM. Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. Endocr Relat Cancer. 2012 Dec; 19(6):759-77. PMID: 22993077.
      View in: PubMed
    34. Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ, deVere White RW. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene. 2013 Aug 29; 32(35):4130-8. PMID: 23069658.
      View in: PubMed
    35. Vinall RL, Kent MS, deVere White RW. Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. Am J Vet Res. 2012 Oct; 73(10):1626-33. PMID: 23013190.
      View in: PubMed
    36. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate. 2013 Mar; 73(4):418-27. PMID: 22996738.
      View in: PubMed
    37. Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN, de Vere White R, Lam KS, Pan CX. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int J Nanomedicine. 2012; 7:2793-804. PMID: 22745542.
      View in: PubMed
    38. Jung CJ, Iyengar S, Blahnik KR, Jiang JX, Tahimic C, Torok NJ, de vere White RW, Farnham PJ, Zern M. Human ESC self-renewal promoting microRNAs induce epithelial-mesenchymal transition in hepatocytes by controlling the PTEN and TGFß tumor suppressor signaling pathways. Mol Cancer Res. 2012 Jul; 10(7):979-91. PMID: 22622027.
      View in: PubMed
    39. Vinall RL, Chen JQ, Hubbard NE, Sulaimon SS, Shen MM, Devere White RW, Borowsky AD. Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression. Dis Model Mech. 2012 Nov; 5(6):914-20. PMID: 22563073.
      View in: PubMed
    40. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One. 2012; 7(3):e32832. PMID: 22479342.
      View in: PubMed
    41. Jacobson MC, deVere White R, Demos SG. In vivo testing of a prototype system providing simultaneous white light and near infrared autofluorescence image acquisition for detection of bladder cancer. J Biomed Opt. 2012 Mar; 17(3):036011. PMID: 22502569.
      View in: PubMed
    42. Falso MJ, Buchholz BA, White RW. Stem-like cells in bladder cancer cell lines with differential sensitivity to cisplatin. Anticancer Res. 2012 Mar; 32(3):733-8. PMID: 22399585.
      View in: PubMed
    43. Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford ED, Thompson IM, Klein EA. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012 Mar; 79(3):633-7. PMID: 22386416.
      View in: PubMed
    44. Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer. 2012 Jun 01; 130(11):2526-38. PMID: 21702042.
      View in: PubMed
    45. Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012 Jan 06; 287(2):1527-37. PMID: 22128178.
      View in: PubMed
    46. Kearney MF, Lee K, Bagni RK, Wiegand A, Spindler J, Maldarelli F, Pinto PA, Linehan WM, Vocke CD, Delviks-Frankenberry KA, Devere White RW, Del Prete GQ, Mellors JW, Lifson JD, Kewalramani VN, Pathak VK, Coffin JM, Le Grice SF. Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples. Adv Virol. 2011; 2011:272193. PMID: 22312339.
      View in: PubMed
    47. Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, deVere White RW, Ghosh PM. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res. 2011 Oct 01; 17(19):6218-28. PMID: 21844010.
      View in: PubMed
    48. Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh PM, Tepper CG, de Vere White RW. Dual blockade of PKA and NF-?B inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm Cancer. 2011 Aug; 2(4):224-38. PMID: 21789713.
      View in: PubMed
    49. Hua S, An HJ, Ozcan S, Ro GS, Soares S, DeVere-White R, Lebrilla CB. Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. Analyst. 2011 Sep 21; 136(18):3663-71. PMID: 21776491.
      View in: PubMed
    50. Heifetz LJ, Christensen SD, Devere-White RW, Meyers FJ. A model for rural oncology. J Oncol Pract. 2011 May; 7(3):168-71. PMID: 21886498.
      View in: PubMed
    51. Shi XB, Xue L, Shi D, deVere White RW. Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor. Cancer Biother Radiopharm. 2011 Apr; 26(2):191-201. PMID: 21539451.
      View in: PubMed
    52. Chamie K, Kurzrock EA, Evans CP, Litwin MS, Koppie TM, Wootton-Gorges SL, Boone JM, Lara PN, Devere White RW. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer. 2011 Sep 15; 117(18):4219-30. PMID: 21412759.
      View in: PubMed
    53. Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011 Sep 15; 129(6):1425-34. PMID: 21128223.
      View in: PubMed
    54. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011 May; 59(5):671-81. PMID: 21296484.
      View in: PubMed
    55. Lin TY, Zhang H, Wang S, Xie L, Li B, Rodriguez CO, de Vere White R, Pan CX. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol Cancer. 2011 Jan 27; 10(1):9. PMID: 21272294.
      View in: PubMed
    56. Hellenthal NJ, Parikh-Patel A, Bauer K, Ralph W, deVere W, Koppie TM. Men of higher socioeconomic status have improved outcomes after radical prostatectomy for localized prostate cancer. Urology. 2010 Dec; 76(6):1409-13. PMID: 20888034.
      View in: PubMed
    57. Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 2011 Sep; 108(5):693-9. PMID: 21105991.
      View in: PubMed
    58. Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN, Turteltaub K, Henderson P, Pan CX. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol. 2010 Nov 15; 23(11):1653-5. PMID: 21028869.
      View in: PubMed
    59. Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol. 2012 Sep; 30(5):635-45. PMID: 20888272.
      View in: PubMed
    60. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate. 2011 Apr; 71(5):538-49. PMID: 20886540.
      View in: PubMed
    61. Li B, Shi XB, Nori D, Chao CK, Chen AM, Valicenti R, White Rde V. Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Prostate. 2011 May; 71(6):567-74. PMID: 20878953.
      View in: PubMed
    62. Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG, Vinall R, Tepper CG, Gandour-Edwards R, Shi X, Lu XH, Siddiqui J, Chinnaiyan AM, Mehra R, Devere White RW, Carraway KL, Ghosh PM. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res. 2010 Jul 15; 70(14):5994-6003. PMID: 20587519.
      View in: PubMed
    63. de Vere White R, Hackman RM, Kugelmass J. The dogmas of nutrition and cancer: time for a second (and maybe third) look. Ann N Y Acad Sci. 2010 Mar; 1190:118-25. PMID: 20388142.
      View in: PubMed
    64. de Vere White R. Words of wisdom. Re: comparative effectiveness of minimally invasive vs open radical prostatectomy. Eur Urol. 2010 Feb; 57(2):355-6. PMID: 20116768.
      View in: PubMed
    65. deVere White RW, Tsodikov A, Stapp EC, Soares SE, Fujii H, Hackman RM. Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr Cancer. 2010; 62(8):1036-43. PMID: 21058191.
      View in: PubMed
    66. Hellenthal NJ, Ramirez ML, Evans CP, Devere White RW. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy. BJU Int. 2010 Feb; 105(4):485-8. PMID: 19849694.
      View in: PubMed
    67. Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, Schelhammer PF, deVere White R, Quale D, Lee CT. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer. 2009 Sep 15; 115(18):4096-103. PMID: 19536899.
      View in: PubMed
    68. DeVere White RW, Vinall RL, Tepper CG, Shi XB. MicroRNAs and their potential for translation in prostate cancer. Urol Oncol. 2009 May-Jun; 27(3):307-11. PMID: 19414119.
      View in: PubMed
    69. deVere White RW, Lara PN, Goldman B, Tangen CM, Smith DC, Wood DP, Hussain MH, Crawford ED. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009 Jun; 181(6):2476-80; discussion 2480-1. PMID: 19371909.
      View in: PubMed
    70. Hellenthal NJ, Ramírez ML, Evans CP, deVere White RW, Koppie TM. Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004. J Urol. 2009 Jun; 181(6):2490-5. PMID: 19371902.
      View in: PubMed
    71. deVere White RW, Katz MH, Steinberg GD. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer. J Urol. 2009 May; 181(5):1994-7. PMID: 19286209.
      View in: PubMed
    72. Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, Prihoda TJ, Siddiqui J, Chinnaiyan AM, Mehra R, de Vere White RW, Ghosh PM. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res. 2009 Feb 01; 15(3):788-96. PMID: 19188148.
      View in: PubMed
    73. Hellenthal NJ, Chamie K, Ramirez ML, deVere White RW. Sociodemographic factors associated with nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 2009 Mar; 181(3):1013-8; discussion 1018-9. PMID: 19150554.
      View in: PubMed
    74. Barkauskas DA, An HJ, Kronewitter SR, de Leoz ML, Chew HK, de Vere White RW, Leiserowitz GS, Miyamoto S, Lebrilla CB, Rocke DM. Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data. Bioinformatics. 2009 Jan 15; 25(2):251-7. PMID: 19073586.
      View in: PubMed
    75. Shi XB, Xue L, Zou JX, Gandour-Edwards R, Chen H, deVere White RW. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells. Prostate. 2008 Dec 01; 68(16):1816-26. PMID: 18780293.
      View in: PubMed
    76. Chamie K, DeVere White RW, Lee D, Ok JH, Ellison LM. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer. 2008 Nov 01; 113(9):2464-70. PMID: 18666213.
      View in: PubMed
    77. Chamie K, Ghosh PM, Koppie TM, Romero V, Troppmann C, deVere White RW. The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer. Am J Transplant. 2008 Dec; 8(12):2668-73. PMID: 18853950.
      View in: PubMed
    78. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008 Nov 27; 27(56):7106-17. PMID: 18776922.
      View in: PubMed
    79. Shi XB, Tepper CG, White RW. MicroRNAs and prostate cancer. J Cell Mol Med. 2008 Sep-Oct; 12(5A):1456-65. PMID: 18624768.
      View in: PubMed
    80. Burich RA, Holland WS, Vinall RL, Tepper C, White RW, Mack PC. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines. BJU Int. 2008 Nov; 102(10):1458-66. PMID: 18565171.
      View in: PubMed
    81. Devlin HL, Mack PC, Burich RA, Gumerlock PH, Kung HJ, Mudryj M, deVere White RW. Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol Cancer Res. 2008 May; 6(5):808-18. PMID: 18505925.
      View in: PubMed
    82. Ramírez ML, Nelson EC, Devere White RW, Lara PN, Evans CP. Current applications for prostate-specific antigen doubling time. Eur Urol. 2008 Aug; 54(2):291-300. PMID: 18439749.
      View in: PubMed
    83. Chamie K, Hu B, Devere White RW, Ellison LM. Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? BJU Int. 2008 Aug; 102(3):284-90. PMID: 18410437.
      View in: PubMed
    84. Shi XB, Tepper CG, deVere White RW. Cancerous miRNAs and their regulation. Cell Cycle. 2008 Jun 01; 7(11):1529-38. PMID: 18469525.
      View in: PubMed
    85. de Leoz ML, An HJ, Kronewitter S, Kim J, Beecroft S, Vinall R, Miyamoto S, de Vere White R, Lam KS, Lebrilla C. Glycomic approach for potential biomarkers on prostate cancer: profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers. 2008; 25(4-5):243-58. PMID: 19126968.
      View in: PubMed
    86. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ, deVere White RW. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19983-8. PMID: 18056640.
      View in: PubMed
    87. Hah SS, Sumbad RA, de Vere White RW, Turteltaub KW, Henderson PT. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. Chem Res Toxicol. 2007 Dec; 20(12):1745-51. PMID: 18001055.
      View in: PubMed
    88. Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN, de Vere White RW. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res. 2007 Oct 15; 13(20):6204-16. PMID: 17947488.
      View in: PubMed
    89. Mudryj M, Reay E, Beckett L, Dandekar S, deVere White R, Gandour-Edwards R. Novel p53/p130 axis in bladder tumors. Urology. 2007 Sep; 70(3):608-12. PMID: 17905135.
      View in: PubMed
    90. Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R, deVere White RW, Kung HJ. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene. 2008 Jan 17; 27(4):499-505. PMID: 17653089.
      View in: PubMed
    91. de Vere White RW. Finasteride for chemoprevention of prostate cancer: why has it not been embraced? J Clin Oncol. 2007 Jul 20; 25(21):2999-3000. PMID: 17634478.
      View in: PubMed
    92. Cambio AJ, Ellison LM, Chamie K, deVere White RW, Evans CP. Cost-benefit and outcome analysis: effect of prostate biopsy undergrading. Urology. 2007 Jun; 69(6):1152-6. PMID: 17572205.
      View in: PubMed
    93. Shi XB, Xue L, Tepper CG, Gandour-Edwards R, Ghosh P, Kung HJ, DeVere White RW. The oncogenic potential of a prostate cancer-derived androgen receptor mutant. Prostate. 2007 May 01; 67(6):591-602. PMID: 17262801.
      View in: PubMed
    94. Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(4):331-9. PMID: 17471291.
      View in: PubMed
    95. Wang Y, Kreisberg JI, Bedolla RG, Mikhailova M, deVere White RW, Ghosh PM. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene. 2007 Sep 06; 26(41):6061-70. PMID: 17420725.
      View in: PubMed
    96. Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate. 2007 Apr 01; 67(5):521-35. PMID: 17252539.
      View in: PubMed
    97. Liao YC, Si L, deVere White RW, Lo SH. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol. 2007 Jan 01; 176(1):43-9. PMID: 17190795.
      View in: PubMed
    98. Zou JX, Zhong Z, Shi XB, Tepper CG, deVere White RW, Kung HJ, Chen H. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes. Prostate. 2006 Oct 01; 66(14):1474-86. PMID: 16921507.
      View in: PubMed
    99. Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW, Karnad AB, Glode M, Crawford ED. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. Oncol Rep. 2006 Oct; 16(4):807-10. PMID: 16969498.
      View in: PubMed
    100. Lara PN, de Vere White R. Accrual issues in genitourinary cancer clinical trials. Urol Oncol. 2006 Sep-Oct; 24(5):379-83. PMID: 16962485.
      View in: PubMed
    101. Ma AH, Xia L, Desai SJ, Boucher DL, Guan Y, Shih HM, Shi XB, deVere White RW, Chen HW, Tepper CG, Kung HJ. Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells. Cancer Res. 2006 Sep 01; 66(17):8439-47. PMID: 16951154.
      View in: PubMed
    102. Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R. Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia. 2006 Sep; 8(9):708-15. PMID: 16984728.
      View in: PubMed
    103. Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL, Albrecht H, De Vere White RW, De Nardo SJ. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. Int J Oncol. 2006 Jul; 29(1):49-55. PMID: 16773184.
      View in: PubMed
    104. Hah SS, Stivers KM, de Vere White RW, Henderson PT. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. Chem Res Toxicol. 2006 May; 19(5):622-6. PMID: 16696564.
      View in: PubMed
    105. Devere White RW. Transurethral resection of superficial bladder cancer using 5-aminolevulinic acid: are there any long-term benefits? Nat Clin Pract Urol. 2006 May; 3(5):254-5. PMID: 16691236.
      View in: PubMed
    106. Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R, de Vere White RW. The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene. 2006 Mar 30; 25(14):2082-93. PMID: 16434975.
      View in: PubMed
    107. You Z, Shi XB, DuRaine G, Haudenschild D, Tepper CG, Lo SH, Gandour-Edwards R, de Vere White RW, Reddi AH. Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer. Cancer Res. 2006 Jan 01; 66(1):175-83. PMID: 16397230.
      View in: PubMed
    108. Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE, Desprez PY, Kung HJ, deVere White RW. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate. 2005 Dec 01; 65(4):375-89. PMID: 16037992.
      View in: PubMed
    109. Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med. 2005 Jul; 2(4):532-40; discussion 540-2. PMID: 16422848.
      View in: PubMed
    110. DeLair SM, White RW, Kurzrock EA. Secondary transitional cell carcinoma and nitrogen mustard treatment. Urology. 2005 Jun; 65(6):1226-7. PMID: 15922437.
      View in: PubMed
    111. Javidan J, Deitch AD, Shi XB, de Vere White RW. The androgen receptor and mechanisms for androgen independence in prostate cancer. Cancer Invest. 2005; 23(6):520-8. PMID: 16203660.
      View in: PubMed
    112. Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res. 2005 Jan 01; 65(1):54-65. PMID: 15665279.
      View in: PubMed
    113. Shi XB, Gandour-Edwards R, Beckett LA, Deitch AD, de Vere White RW. A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value. BJU Int. 2004 Nov; 94(7):996-1002. PMID: 15541116.
      View in: PubMed
    114. Karpman E, Goldberg Z, Saffarian A, Gandour-Edwards R, Ellison LM, deVere White RW. Analysis of treatment for small cell cancer of the bladder and report of three cases. Urology. 2004 Sep; 64(3):494-8. PMID: 15351578.
      View in: PubMed
    115. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Kung HJ, deVere White RW. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate. 2004 Aug 01; 60(3):257-71. PMID: 15176055.
      View in: PubMed
    116. Demos SG, Gandour-Edwards R, Ramsamooj R, deVere White R. Spectroscopic detection of bladder cancer using near-infrared imaging techniques. J Biomed Opt. 2004 Jul-Aug; 9(4):767-71. PMID: 15250764.
      View in: PubMed
    117. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004 Jul 15; 22(14):2781-9. PMID: 15199091.
      View in: PubMed
    118. Demos SG, Gandour-Edwards R, Ramsamooj R, White Rd. Near-infrared autofluorescence imaging for detection of cancer. J Biomed Opt. 2004 May-Jun; 9(3):587-92. PMID: 15189097.
      View in: PubMed
    119. Madewell BR, Gandour-Edwards R, DeVere White RW. Canine prostatic intraepithelial neoplasia: is the comparative model relevant? Prostate. 2004 Feb 15; 58(3):314-7. PMID: 14743472.
      View in: PubMed
    120. deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology. 2004 Feb; 63(2):259-63. PMID: 14972467.
      View in: PubMed
    121. Gandour-Edwards R, Mack PC, Devere-White RW, Gumerlock PH. Abnormalities of apoptotic and cell cycle regulatory proteins in distinct histopathologic components of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2004; 7(4):321-6. PMID: 15314639.
      View in: PubMed
    122. Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, Sweeney C. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int. 2004 Jan; 93(1):143-50. PMID: 14678387.
      View in: PubMed
    123. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28; 349(9):859-66. PMID: 12944571.
      View in: PubMed
    124. Nesslinger NJ, Shi XB, deVere White RW. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res. 2003 May 01; 63(9):2228-33. PMID: 12727844.
      View in: PubMed
    125. Highshaw RA, Tanaka ST, Evans CP, deVere White RW. Is bladder biopsy necessary at three or six months post BCG therapy? Urol Oncol. 2003 May-Jun; 21(3):207-9. PMID: 12810207.
      View in: PubMed
    126. Shi XB, Di Mauro SM, Highshaw R, Deitch AD, Evans CP, Gumerlock PH, deVere White RW. Application of a yeast assay to detect functional p53 mutations in archival prostate cancer tissue. Cancer Biother Radiopharm. 2002 Dec; 17(6):657-64. PMID: 12537669.
      View in: PubMed
    127. Scott SL, Higdon R, Beckett L, Shi XB, deVere White RW, Earle JD, Gumerlock PH. BCL2 antisense reduces prostate cancer cell survival following irradiation. Cancer Biother Radiopharm. 2002 Dec; 17(6):647-56. PMID: 12537668.
      View in: PubMed
    128. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, DeVERE WHITE R, Thompson IM, Crawford ED. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol. 2002 Nov; 168(5):2016-9. PMID: 12394698.
      View in: PubMed
    129. deVere White RW, Hackman RM, Soares SE, Beckett LA, Sun B. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology. 2002 Oct; 60(4):640-4. PMID: 12385925.
      View in: PubMed
    130. Gandour-Edwards R, Lara PN, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer. 2002 Sep 01; 95(5):1009-15. PMID: 12209684.
      View in: PubMed
    131. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, deVere White RW. Complex functions of mutant p53 alleles from human prostate cancer. Prostate. 2002 Apr 01; 51(1):59-72. PMID: 11920959.
      View in: PubMed
    132. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002 Mar 01; 62(5):1496-502. PMID: 11888926.
      View in: PubMed
    133. Eandi JA, de Vere White RW, Tunuguntla HS, Bohringer CH, Evans CP. Can single dose preoperative intrathecal morphine sulfate provide cost-effective postoperative analgesia and patient satisfaction during radical prostatectomy in the current era of cost containment? Prostate Cancer Prostatic Dis. 2002; 5(3):226-30. PMID: 12496986.
      View in: PubMed
    134. Shi XB, Gumerlock PH, Muenzer JT, deVere White RW. BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents. Cancer Biother Radiopharm. 2001 Oct; 16(5):421-9. PMID: 11776759.
      View in: PubMed
    135. Liu HL, Gandour-Edwards R, Lara PN, de Vere White R, LaSalle JM. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J. 2001 Sep-Oct; 7(5):395-403. PMID: 11693898.
      View in: PubMed
    136. Williams SG, Gandour-Edwards R, Deitch AD, Toscano S, Fan JJ, Sternberg CN, Pansadoro V, Calabrò F, Rossetti A, deVere White RW. Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients. Eur Urol. 2001 Apr; 39(4):430-7. PMID: 11306882.
      View in: PubMed
    137. Wilder RB, Chou RH, Ryu JK, Stern RL, Wong MS, Ji M, Roach M, White RD. Potency preservation after three-dimensional conformal radiotherapy for prostate cancer: preliminary results. Am J Clin Oncol. 2000 Aug; 23(4):330-3. PMID: 10955856.
      View in: PubMed
    138. Hall WH, McGahan JP, Link DP, deVere White RW. Combined embolization and percutaneous radiofrequency ablation of a solid renal tumor. AJR Am J Roentgenol. 2000 Jun; 174(6):1592-4. PMID: 10845488.
      View in: PubMed
    139. Dow JK, deVere White RW. Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology. 2000 Jun; 55(6):800-6. PMID: 10840080.
      View in: PubMed
    140. deVere White RW, Deitch AD, Daneshmand S, Blumenstein B, Lowe BA, Sagalowsky AI, Smith JA, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED. The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study. Eur Urol. 2000 May; 37(5):595-600. PMID: 10765099.
      View in: PubMed
    141. Wilder RB, Hsiang JY, Ji M, Earle JD, de Vere White R. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy. Am J Clin Oncol. 2000 Apr; 23(2):176-80. PMID: 10776980.
      View in: PubMed
    142. Chou RH, Wilder RB, Ji M, Ryu JK, Leigh BR, Earle JD, Doggett RL, Kubo HD, Roach M, deVere White RW. Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy. Int J Radiat Oncol Biol Phys. 2000 Apr 01; 47(1):115-9. PMID: 10758312.
      View in: PubMed
    143. Edelman MJ, Meyers FJ, Miller TR, Williams SG, Gandour-Edwards R, deVere White RW. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology. 2000 Apr; 55(4):521-5. PMID: 10736495.
      View in: PubMed
    144. de Vere White R. Present and future management of prostate cancer. Cancer Biother Radiopharm. 2000 Apr; 15(2):121-5. PMID: 10803316.
      View in: PubMed
    145. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, Melman A, Bracken RB, deVere White R, Taylor A, Wang D, Waldstreicher J. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology. 1999 Oct; 54(4):662-9. PMID: 10510925.
      View in: PubMed
    146. deVere White RW, Deitch AD, Gumerlock PH, Shi XB. Use of a yeast assay to detect functional alterations in p53 in prostate cancer: review and future directions. Prostate. 1999 Oct 01; 41(2):134-42. PMID: 10477910.
      View in: PubMed
    147. Hegarty NJ, Fitzpatrick JM, Richie JP, Scardino PT, deVere White RW, Schröder FH, Coffey DS. Future prospects in prostate cancer. Prostate. 1999 Sep 01; 40(4):261-8. PMID: 10420155.
      View in: PubMed
    148. Huang A, Fone PD, Gandour-Edwards R, White RW, Low RK. Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma. J Urol. 1999 Aug; 162(2):610-3. PMID: 10411096.
      View in: PubMed
    149. Gumbiner LM, Gumerlock PH, Mack PC, Chi SG, deVere White RW, Mohler JL, Pretlow TG, Tricoli JV. Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate. 1999 Jan 01; 38(1):40-5. PMID: 9973108.
      View in: PubMed
    150. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer. 1998 Dec 15; 83(12):2534-9. PMID: 9874460.
      View in: PubMed
    151. de Vere White RW, Stapp E. Predicting prognosis in patients with superficial bladder cancer. Oncology (Williston Park). 1998 Dec; 12(12):1717-23; discussion 1724-6. PMID: 9874845.
      View in: PubMed
    152. Meyers FJ, DeVere White RW. Prostate carcinoma: clarification through clinical insight and molecular diagnostics. West J Med. 1998 Jun; 168(6):525. PMID: 9655997.
      View in: PubMed
    153. deVere White RW, Deitch AD, Jackson AG, Gandour-Edwards R, Marshalleck J, Soares SE, Toscano SN, Lunetta JM, Stewart SL. Racial differences in clinically localized prostate cancers of black and white men. J Urol. 1998 Jun; 159(6):1979-82; discussion 1982-3. PMID: 9598502.
      View in: PubMed
    154. Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD, White RW. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology. 1998 Feb; 51(2):346-51. PMID: 9495727.
      View in: PubMed
    155. Mack PC, Chi SG, Meyers FJ, Stewart SL, deVere White RW, Gumerlock PH. Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate. 1998 Feb 01; 34(2):145-51. PMID: 9465946.
      View in: PubMed
    156. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology. 1997 Dec; 50(6):882-7. PMID: 9426718.
      View in: PubMed
    157. Chi SG, deVere White RW, Muenzer JT, Gumerlock PH. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. Clin Cancer Res. 1997 Oct; 3(10):1889-97. PMID: 9815578.
      View in: PubMed
    158. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere White R, Sheinfeld J, Jarowenko MV, Schellhammer PF, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M, Adams G, Blumenstein BA, Thoelke KR, Pfalzgraf RD, Murchison HA, Brunelle SL. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology. 1997 Sep; 50(3):349-53. PMID: 9301696.
      View in: PubMed
    159. Wilder RB, Fone PD, Rademacher DE, Jones CD, Roach M, Earle JD, White RD. Localization of the prostatic apex for radiotherapy treatment planning using urethroscopy. Int J Radiat Oncol Biol Phys. 1997 Jul 01; 38(4):737-41. PMID: 9240640.
      View in: PubMed
    160. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol. 1997 Apr; 11(4):450-9. PMID: 9092797.
      View in: PubMed
    161. de Vere White R, Meyers F, Chi SG, Chamberlain S, Siders D, Lee F, Stewart S, Gumerlock PH. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol. 1997; 31(1):1-6. PMID: 9032526.
      View in: PubMed
    162. Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, deVere White RW. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J Natl Cancer Inst. 1997 Jan 01; 89(1):66-71. PMID: 8978408.
      View in: PubMed
    163. Litwiller SE, Kim KB, Fone PD, White RW, Stone AR. Post-prostatectomy incontinence and the artificial urinary sphincter: a long-term study of patient satisfaction and criteria for success. J Urol. 1996 Dec; 156(6):1975-80. PMID: 8911369.
      View in: PubMed
    164. Shi XB, Bodner SM, deVere White RW, Gumerlock PH. Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay. Diagn Mol Pathol. 1996 Dec; 5(4):271-8. PMID: 8955619.
      View in: PubMed
    165. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res. 1996 Jul 01; 56(13):3042-6. PMID: 8674060.
      View in: PubMed
    166. Wertz IE, Deitch AD, Gumerlock PH, Gandour-Edwards R, Chi SG, de Vere White RW. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol. 1996 Jun; 27(6):573-80. PMID: 8666367.
      View in: PubMed
    167. Borchers H, Meyers FJ, Gumerlock PH, Stewart SL, deVere White RW. NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: altered expression in combined androgen blockaded carcinomas. J Urol. 1996 Jun; 155(6):2080-4. PMID: 8618340.
      View in: PubMed
    168. Glick SH, Howell LP, White RW. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol. 1996 May; 155(5):1754-7. PMID: 8627878.
      View in: PubMed
    169. Tricoli JV, Gumerlock PH, Yao JL, Chi SG, D'Souza SA, Nestok BR, deVere White RW. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer. 1996 Feb; 15(2):108-14. PMID: 8834174.
      View in: PubMed
    170. Devere White RW, Deitch AD, Tesluk H, Blumensteinj B, Lowe BA, Sagalowsky AI, Smith JA, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED. Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study. Urol Oncol. 1996 Jan-Feb; 2(1):27-34. PMID: 21224132.
      View in: PubMed
    171. DeNardo SJ, Gumerlock PH, Winthrop MD, Mack PC, Chi SG, Lamborn KR, Shen S, Miers LA, deVere White RW, DeNardo GL. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression. Cancer Res. 1995 Dec 01; 55(23 Suppl):5837s-5841s. PMID: 7493356.
      View in: PubMed
    172. Sarosdy MF, deVere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF, Jarowenko MV, Adams G, Blumenstein BA. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol. 1995 Aug; 154(2 Pt 1):379-83; discussion 383-4. PMID: 7609102.
      View in: PubMed
    173. Huang A, Low RK, deVere White R. Nephrostomy tract tumor seeding following percutaneous manipulation of a ureteral carcinoma. J Urol. 1995 Mar; 153(3 Pt 2):1041-2. PMID: 7853555.
      View in: PubMed
    174. Fishman JR, Gumerlock PH, Meyers FJ, deVere White RW. Quantitation of NM23 expression in human prostate tissues. J Urol. 1994 Jul; 152(1):202-7. PMID: 7515452.
      View in: PubMed
    175. Chi SG, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst. 1994 Jun 15; 86(12):926-33. PMID: 7515114.
      View in: PubMed
    176. Meyers FJ, Chi SG, Fishman JR, deVere White RW, Gumerlock PH. p53 mutations in benign prostatic hyperplasia. J Natl Cancer Inst. 1993 Nov 17; 85(22):1856-8. PMID: 7693956.
      View in: PubMed
    177. Deitch AD, de Vere White RW, Madewell BR. False DNA aneuploidy in canine and human neoplasms. Anticancer Res. 1993 Nov-Dec; 13(6A):2117-8. PMID: 8297122.
      View in: PubMed
    178. Deitch AD, Miller GJ, deVere White RW. Significance of abnormal diploid DNA histograms in localized prostate cancer and adjacent benign prostatic tissue. Cancer. 1993 Sep 01; 72(5):1692-700. PMID: 7688657.
      View in: PubMed
    179. McGahan JP, Blake LC, deVere White R, Gerscovich EO, Brant WE. Color flow sonographic mapping of intravascular extension of malignant renal tumors. J Ultrasound Med. 1993 Jul; 12(7):403-9. PMID: 8394940.
      View in: PubMed
    180. Couillard DR, deVere White RW. Surgery of renal cell carcinoma. Urol Clin North Am. 1993 May; 20(2):263-75. PMID: 8493749.
      View in: PubMed
    181. Howell LP, Deitch AD, Andreotti VA, Westrick LA, White RD. Fixation method useful for cytologic examination and DNA flow cytometry of exfoliated bladder cells. Urology. 1993 May; 41(5):472-5. PMID: 7683835.
      View in: PubMed
    182. Fishman JR, Walton DT, Flynn NM, Benson DR, deVere White RW. Tuberculous spondylitis as a complication of intravesical bacillus Calmette-Guerin therapy. J Urol. 1993 Mar; 149(3):584-7. PMID: 8437271.
      View in: PubMed
    183. Wheeless LL, Badalament RA, de Vere White RW, Fradet Y, Tribukait B. Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference. Cytometry. 1993; 14(5):478-81. PMID: 8354118.
      View in: PubMed
    184. Amberson JB, Laino JP. Image cytometric deoxyribonucleic acid analysis of urine specimens as an adjunct to visual cytology in the detection of urothelial cell carcinoma. J Urol. 1993 Jan; 149(1):42-5. PMID: 8417214.
      View in: PubMed
    185. Norming U, Tribukait B, Nyman CR, Nilsson B, Wang N. Prognostic significance of mucosal aneuploidy in stage Ta/T1 grade 3 carcinoma of the bladder. J Urol. 1992 Nov; 148(5):1420-6; discussion 1426-7. PMID: 1433541.
      View in: PubMed
    186. Waehre H, Amellem O, Stenwig AE, Tverå K, Juul M, Pettersen EO, Fosså SD. Deoxyribonucleic acid cytometry and histological findings before and after 125iodine implantation of primary prostate cancer. J Urol. 1992 Sep; 148(3):838-41; discussion 841-2. PMID: 1512835.
      View in: PubMed
    187. Meloni AM, Sandberg AA, White RD. -Y,-1 as recurrent anomaly in oncocytoma. Cancer Genet Cytogenet. 1992 Jul 01; 61(1):108-9. PMID: 1638476.
      View in: PubMed
    188. Deitch AD, deVere White RW. Flow cytometry as a predictive modality in prostate cancer. Hum Pathol. 1992 Apr; 23(4):352-9. PMID: 1563735.
      View in: PubMed
    189. DeVere White RW, Meyers FJ, Soares SE, Miller DG, Soriano TF. Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy. J Urol. 1992 Mar; 147(3 Pt 2):947-51. PMID: 1371566.
      View in: PubMed
    190. deVere White RW, Deitch AD. Evaluation of DNA flow cytometry as a screening test for bladder cancer. J Cell Biochem Suppl. 1992; 16I:80-4. PMID: 1305694.
      View in: PubMed
    191. Sheinfeld J, Herr HW. Intervention strategies for chemoprevention of bladder cancer. J Cell Biochem Suppl. 1992; 16I:173-4. PMID: 1305683.
      View in: PubMed
    192. Broderick GA, McGahan JP, Stone AR, White RD. The hemodynamics of vacuum constriction erections: assessment by color Doppler ultrasound. J Urol. 1992 Jan; 147(1):57-61. PMID: 1729552.
      View in: PubMed
    193. Meyers FJ, Gumerlock PH, Kawasaki ES, Wang AM, deVere White RW, Erlich HA. Bladder cancer. Human leukocyte antigen II, interleukin-6, and interleukin-6 receptor expression determined by the polymerase chain reaction. Cancer. 1991 Apr 15; 67(8):2087-95. PMID: 2004327.
      View in: PubMed
    194. Gumerlock PH, Poonamallee UR, Meyers FJ, deVere White RW. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res. 1991 Mar 15; 51(6):1632-7. PMID: 1998954.
      View in: PubMed
    195. Wheeless LL, Coon JS, Cox C, Deitch AD, deVere White RW, Fradet Y, Koss LG, Melamed MR, O'Connell MJ, Reeder JE. Precision of DNA flow cytometry in inter-institutional analyses. Cytometry. 1991; 12(5):405-12. PMID: 1935456.
      View in: PubMed
    196. Madewell BR, Deitch AD, Higgins RJ, Marks SL, deVere White RW. DNA flow cytometric study of the hyperplastic and neoplastic canine prostate. Prostate. 1991; 18(2):173-9. PMID: 1706513.
      View in: PubMed
    197. Broderick GA, Stone AR, deVere White R. Neobladders: clinical management and considerations for patients receiving chemotherapy. Semin Oncol. 1990 Oct; 17(5):598-605. PMID: 2218572.
      View in: PubMed
    198. Deitch AD, Anderson KA, deVere White RW. Evaluation of DNA flow cytometry as a screening test for bladder cancer. J Occup Med. 1990 Sep; 32(9):898-903. PMID: 2074516.
      View in: PubMed
    199. deVere White RW. Neoadjuvant therapy of carcinoma of the bladder. Semin Urol. 1990 Aug; 8(3):197-200. PMID: 2204981.
      View in: PubMed
    200. Hellstrom WJ, Tesluk H, Deitch AD, de Vere White RW. Comparison of flow cytometry to routine testicular biopsy in male infertility. Urology. 1990 Apr; 35(4):321-6. PMID: 2321325.
      View in: PubMed
    201. Deitch AD, Andreotti VA, Strand MA, Howell L, deVere White RW. A clinically applicable method to preserve urine and bladder washing cells for flow cytometric monitoring of bladder cancer patients. J Urol. 1990 Apr; 143(4):700-5. PMID: 2179581.
      View in: PubMed
    202. Howell LP, Amott TR, deVere-White R. Aspiration biopsy cytology of the prostate in young adult men. Diagn Cytopathol. 1990; 6(2):89-94. PMID: 2338041.
      View in: PubMed
    203. Meyers FJ, Gumerlock PH, Teplitz RL, Hatcher SL, deVere White RW. Sequential flow cytometry and single gene analysis by enzymatic amplification and allele specific oligonucleotide hybridization of urothelial cells. J Urol. 1989 Dec; 142(6):1599-601. PMID: 2585644.
      View in: PubMed
    204. Wheeless LL, Coon JS, Cox C, Deitch AD, de Vere White RW, Koss LG, Melamed MR, O'Connell MJ, Reeder JE, Weinstein RS. Measurement variability in DNA flow cytometry of replicate samples. Cytometry. 1989 Nov; 10(6):731-8. PMID: 2582964.
      View in: PubMed
    205. Deitch AD, Strand MA, de Vere White RW. Deoxyribonucleic acid flow cytometry of benign prostatic disease. J Urol. 1989 Sep; 142(3):759-62. PMID: 2769856.
      View in: PubMed
    206. Wolach MD, MacDermott JP, Stone AR, deVere White RW. Treatment and complications of Fournier's gangrene. Br J Urol. 1989 Sep; 64(3):310-4. PMID: 2804566.
      View in: PubMed
    207. Hellstrom WJ, Stone AR, Deitch AD, deVere White RW. The clinical application of aspiration deoxyribonucleic acid flow cytometry to neurologically impaired men entering an electroejaculation program. J Urol. 1989 Aug; 142(2 Pt 1):309-12. PMID: 2787410.
      View in: PubMed
    208. Gumerlock PH, Meyers FJ, Kokoris SP, Wong G, McCormick FP, de Vere White RW. RAS enzyme-linked immunoblot assay discriminates p21 species: a technique to dissect gene family expression. Anal Biochem. 1989 Jul; 180(1):158-68. PMID: 2683857.
      View in: PubMed
    209. Meyers FJ, Gumerlock PH, Kokoris SP, deVere White RW, McCormick F. Human bladder and colon carcinomas contain activated ras p21. Specific detection of twelfth codon mutants. Cancer. 1989 Jun 01; 63(11):2177-81. PMID: 2655864.
      View in: PubMed
    210. Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol. 1989 Jun; 7(6):700-5. PMID: 2523957.
      View in: PubMed
    211. Hermansen DK, Melamed MR, Coon JS, Weinstein RS, White RD, Deitch AD, Wheeless LL, Reeder JE, Wersto R, Koss LG. Ethanol fixation of bladder irrigation specimens for flow cytometric analysis. A multiinstitutional study from the bladder cancer flow cytometry network. Cancer. 1989 May 01; 63(9):1780-3. PMID: 2702585.
      View in: PubMed
    212. Coon JS, Deitch AD, de Vere White RW, Koss LG, Melamed MR, Reeder JE, Weinstein RS, Wersto RP, Wheeless LL. Check samples for laboratory self-assessment in DNA flow cytometry. The National Cancer Institute's Flow Cytometry Network experience. Cancer. 1989 Apr 15; 63(8):1592-9. PMID: 2924266.
      View in: PubMed
    213. Hellstrom WJ, Deitch AD, deVere White RW. Evaluation of vasovasostomy candidates by deoxyribonucleic acid flow cytometry of testicular aspirates. Fertil Steril. 1989 Mar; 51(3):546-8. PMID: 2920857.
      View in: PubMed
    214. Hijazi A, Devonec M, Bouvier R, Revillard JP. Flow cytometry study of cytokeratin 18 expression according to tumor grade and deoxyribonucleic acid content in human bladder tumors. J Urol. 1989 Mar; 141(3):522-6. PMID: 2465418.
      View in: PubMed
    215. Gumerlock PH, Meyers FJ, Foster BA, Kawakami TG, deVere White RW. Activated c-N-ras in radiation-induced acute nonlymphocytic leukemia: twelfth codon aspartic acid. Radiat Res. 1989 Feb; 117(2):198-206. PMID: 2646654.
      View in: PubMed
    216. Meyers FJ, Denardo SJ, Macey D, White RD, Unger M. Development of monoclonal antibody imaging of metastatic prostatic carcinoma. Prostate. 1989; 14(3):209-20. PMID: 2471962.
      View in: PubMed
    217. Wheeless LL, Coon JS, Deitch AD, deVere White RW, Koss LG, Melamed MR, Reeder JE, Robinson RD, Weinstein RS, Wersto RP. Comparison of automated and manual techniques for analysis of DNA frequency distributions in bladder washings. Cytometry. 1988 Nov; 9(6):600-4. PMID: 3208625.
      View in: PubMed
    218. Baker WC, deVere White R, Rossitto PV, Min BH, Cardiff RD. Quantitative analysis of keratin 18 in the urine of patients with bladder cancer. J Urol. 1988 Aug; 140(2):436-9. PMID: 2456406.
      View in: PubMed
    219. Rossitto PV, Chan R, Strand MA, Miller CH, Baker WC, Deitch AD, deVere White R, Cardiff RD. Characterization of urinary keratin number 18 using a new assay. J Urol. 1988 Aug; 140(2):431-5. PMID: 2456405.
      View in: PubMed
    220. deVere White RW, Deitch AD, Baker WC, Strand MA. Urine: a suitable sample for deoxyribonucleic acid flow cytometry studies in patients with bladder cancer. J Urol. 1988 May; 139(5):926-8. PMID: 3361665.
      View in: PubMed
    221. Baker WC, Goldman LB, deVere White RW. Pseudomyxoma peritonei presenting as a scrotal mass. J Urol. 1988 Apr; 139(4):821-2. PMID: 3352057.
      View in: PubMed
    222. Sawczuk IS, Olsson CA, deVere White R. The limited usefulness of external beam radiotherapy in the control of superficial bladder cancer. Br J Urol. 1988 Apr; 61(4):330-2. PMID: 3382886.
      View in: PubMed
    223. Baker WC, Meyers FJ, White RW. Prostatic-specific antigen: clinical experience utilizing immunoperoxidase staining techniques in patients with metastatic prostate cancer. J Surg Oncol. 1988 Mar; 37(3):165-7. PMID: 2451087.
      View in: PubMed
    224. deVere White RW, Deitch AD, West B, Fitzpatrick JM. The predictive value of flow cytometric information in the clinical management of stage O (Ta) bladder cancer. J Urol. 1988 Feb; 139(2):279-82. PMID: 3339725.
      View in: PubMed
    225. Baker WC, Bishai MB, DeVere White RW. Misleading testicular masses. Urology. 1988 Feb; 31(2):111-3. PMID: 3277324.
      View in: PubMed
    226. Baker WC, Russo MA, deVere White RW. Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer. Urology. 1987 Oct; 30(4):357-8. PMID: 3116739.
      View in: PubMed
    227. Sherman RH, Goldman LB, deVere White RW. Filarial chyluria as a cause of acute urinary retention. Urology. 1987 Jun; 29(6):642-5. PMID: 3576897.
      View in: PubMed
    228. deVere White RW, Olsson CA, Deitch AD. Flow cytometry: role in monitoring transitional cell carcinoma of bladder. Urology. 1986 Jul; 28(1):15-20. PMID: 3727223.
      View in: PubMed
    229. Sawczuk I, Acosta R, Grant D, White RD. Post urethroplasty squamous cell carcinoma. N Y State J Med. 1986 May; 86(5):261-3. PMID: 3459083.
      View in: PubMed
    230. Sawczuk IS, Reitelman C, Libby C, Grant D, Vita J, White RD. CT findings in Addison's disease caused by tuberculosis. Urol Radiol. 1986; 8(1):44-5. PMID: 3727207.
      View in: PubMed
    231. Nagler HM, Li XZ, Lizza EF, Deitch A, White RD. Varicocele: temporal considerations. J Urol. 1985 Aug; 134(2):411-3. PMID: 4020998.
      View in: PubMed
    232. Tomashefsky P, Astor M, White RD. Relationship between thiol depletion and chemosensitization in a transplantable murine bladder tumor. J Natl Cancer Inst. 1985 Jun; 74(6):1233-8. PMID: 3858595.
      View in: PubMed
    233. deVere White RW, Deitch AD. The role of flow cytometry in urologic disease. Semin Urol. 1985 May; 3(2):132-45. PMID: 3916558.
      View in: PubMed
    234. Sawczuk I, Tannenbaum M, Olsson CA, deVere White R. Primary transitional cell carcinoma of prostatic periurethral ducts. Urology. 1985 Apr; 25(4):339-43. PMID: 3885546.
      View in: PubMed
    235. deVere White R, Deitch AD, Hong WK, Olsson CA. The influence of cytoreductive surgery on the response to chemotherapy of a rat renal cancer. Urol Res. 1985; 13(1):35-8. PMID: 3992765.
      View in: PubMed
    236. Goldberg SD, Deitch AD, Schevchuck M, Nagler HM, deVere White R. Comparison of histologic and flow cytometric evaluation of cyclophosphamide-induced testicular damage. Urology. 1984 Nov; 24(5):472-5. PMID: 6495459.
      View in: PubMed
    237. deVere White R. Nonsurgical management of patients with stage D1 adenocarcinoma of prostate: risks vs benefits. Urology. 1984 Nov; 24(5 Suppl):12-5. PMID: 6541825.
      View in: PubMed
    238. Nagler HM, Deitch AD, deVere White R. Testicular torsion: temporal considerations. Fertil Steril. 1984 Aug; 42(2):257-62. PMID: 6745459.
      View in: PubMed
    239. Buttyan R, Tomashefsky P, Deitch AD, Olsson CA, Devere-White R. Alterations of physical and biochemical parameters of the R3327-CP rat prostate adenocarcinoma following hormonal manipulation of the host. J Urol. 1984 Jun; 131(6):1218-24. PMID: 6726931.
      View in: PubMed
    240. Nagler HM, deVere White R, Roberts M. Familial idiopathic priapism: a case report. J Urol. 1984 Mar; 131(3):542-3. PMID: 6700001.
      View in: PubMed
    241. White RD, Romas NA, Tomashefsky P, Hall EJ, Olsson CA. Misonidazole as a chemosensitizer in the treatment of the Dunning prostate cancer model. J Urol. 1984 Feb; 131(2):374-7. PMID: 6699977.
      View in: PubMed
    242. deVere White R. The impact of lymphnode metastases in renal adenocarcinoma: prognostic impact and effect of lymphadenectomy. Prog Clin Biol Res. 1984; 153:437-9. PMID: 6473406.
      View in: PubMed
    243. Nagler HM, deVere White R, Dyrenfurth I, Hembree WC. The effect of delta 1-testolactone on serum testosterone and estradiol in the adult male rat. Fertil Steril. 1983 Dec; 40(6):818-22. PMID: 6653801.
      View in: PubMed
    244. deVere White R. Radiation and chemotherapy for stage D1 prostate cancer. Semin Urol. 1983 Nov; 1(4):261-8. PMID: 6399612.
      View in: PubMed
    245. deVere White R, Babayan RK, Krikorian J, Krane RJ, Olsson CA. Adjuvant chemotherapy for stage D1 adenocarcinoma of prostate. Urology. 1983 Mar; 21(3):270-2. PMID: 6836806.
      View in: PubMed
    246. deVere White R, Deitch AD, Olsson CA. Limitations of DNA histogram analysis by flow cytometry as a method of predicting chemosensitivity in a rat renal cancer model. Cancer Res. 1983 Feb; 43(2):604-10. PMID: 6293701.
      View in: PubMed
    247. deVere White R, O'Brien M, Krikorian J, Babayan R, Olsson CA. Maytansine as a cause of acute proliferative disorder of bladder urothelium in the rat. Cancer Treat Rep. 1983 Feb; 67(2):183-4. PMID: 6825127.
      View in: PubMed
    248. Walsh WG, Tomashefsky P, Olsson CA, deVere White R. Keyhole-limpet haemocyanin (KLH) immunotherapy of murine transitional cell carcinoma. Urol Res. 1983; 11(6):263-5. PMID: 6659223.
      View in: PubMed
    249. Sawczuk IS, deVere White R, Gold RP, Olsson CA. Sensitivity of computed tomography in evaluation of pelvic lymph node metastases from carcinoma of bladder and prostate. Urology. 1983 Jan; 21(1):81-4. PMID: 6823714.
      View in: PubMed
    250. Nagler HM, White RD. The effect of testicular torsion on the contralateral testis. J Urol. 1982 Dec; 128(6):1343-8. PMID: 7154207.
      View in: PubMed
    251. Kardon FM, Krikorian JG, Lopez JA, White RD. Errors in measurement and reporting of serum markers in patients with germ cell tumors. Urology. 1982 Nov; 20(5):476-8. PMID: 6183813.
      View in: PubMed
    252. Deitch AD, Law H, deVere White R. A stable propidium iodide staining procedure for flow cytometry. J Histochem Cytochem. 1982 Sep; 30(9):967-72. PMID: 6182188.
      View in: PubMed
    253. de Vere White R, Ki Hong W, Tannenbaum M, Olsson CA. Chemosensitivity of murine renal carcinoma. Urol Res. 1982 Feb; 10(1):27-30. PMID: 7200273.
      View in: PubMed
    254. deVere White R, Karian S, Hong WK, Olsson CA. Testis tumor markers: how accurate are they? J Urol. 1981 May; 125(5):661-3. PMID: 6164799.
      View in: PubMed
    255. White RV, Olsson DA. Renal adenocarcinoma in the rat: a new tumor model. Invest Urol. 1980 Mar; 17(5):405-12. PMID: 7358504.
      View in: PubMed
    256. Baker EL, Goyer RA, Fowler BA, Khettry U, Bernard DB, Adler S, White RD, Babayan R, Feldman RG. Occupational lead exposure, nephropathy, and renal cancer. Am J Ind Med. 1980; 1(2):139-48. PMID: 7342761.
      View in: PubMed
    257. Babayan RK, White RD, Austen G, Krane RJ, Feldman M, Olsson CA. Benefits and complications of staging pelvic lymph node dissection in prostatic adenocarcinoma. Prostate. 1980; 1(3):345-9. PMID: 7279804.
      View in: PubMed
    258. Olsson CA, deVere White R, Goldstein I, Traish AM, Müller RE, Wotiz HH. A preliminary report on the measurement of cytosolic and nuclear prostatic tissue steroid receptors. Prog Clin Biol Res. 1979; 33:209-21. PMID: 93750.
      View in: PubMed
    259. Paulson DF, White RD. Trimethoprium-sulfamethoxazole and minocycline- hydrochloride in the treatment of culture-proved bacterial prostatitis. J Urol. 1978 Aug; 120(2):184-5. PMID: 671629.
      View in: PubMed
    260. White RD, Paulson DF. Staging profile of hypofertile male subjects. J Urol. 1978 Jul; 120(1):71-2. PMID: 671611.
      View in: PubMed
    261. White RD, Cleeve L, Weinerth J. Case profile: unusual complications of radical perineal prostatectomy. Urology. 1978 Jan; 11(1):95. PMID: 414404.
      View in: PubMed
    262. White RD, Previte S, Olsson CA. A new animal model for testing the effectiveness of chemotherapeutic agents on renal adenocarcinoma. Surg Forum. 1978; 29:629-31. PMID: 401284.
      View in: PubMed
    263. Lockhart JL, Wacksman J, White RD, Older RA, Jackson DC, Johnsrude IS, Glenn JF. Renal cyst puncture and abscess formation. Urology. 1977 Aug; 10(2):98-9. PMID: 898464.
      View in: PubMed
    264. White RD, Paulson DF. Obstruction of the male reproductive tract. J Urol. 1977 Aug; 118(2):266-8. PMID: 894804.
      View in: PubMed
    265. Paulson DF, Hammond CB, de Vere White R, Wiebe RH. Clomiphene citrate: pharmacologic treatment of hypofertile male. Urology. 1977 Apr; 9(4):419-21. PMID: 855067.
      View in: PubMed
    266. de Vere White R, Paulson DF, Glenn JF. The clinical spectrum of prostate cancer. J Urol. 1977 Mar; 117(3):323-7. PMID: 839594.
      View in: PubMed
    267. Mullin EM, White RD, Peterson LJ, Paulson DF. Bilateral renal carcinoma in von Hippel-Lindau Disease. Urology. 1976 Nov; 8(5):475-8. PMID: 982734.
      View in: PubMed
    268. de Vere White R, Kelly DG, Duff F. Review of thirty total cystectomys. Ir Med J. 1975 Feb 22; 68(4):90-2. PMID: 1112693.
      View in: PubMed
    269. De Vere White R, Kelly D, Duff F. A review of 200 cases of bladder tumour. J Ir Med Assoc. 1973 Dec 22; 66(24):711-5. PMID: 4776027.
      View in: PubMed